Redeye updates its estimates and fair value range following CTEK’s strong Q2 report published last Friday. The high-margin, low-voltage business beat our sales estimates by far, although we have previously highlighted the potential for the product category. We think the report verifies that CTEK is on track to restoring organic growth and profitability, resulting in a warranted 12% share price increase on Friday.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/